CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• CytomX Therapeutics is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.05) per share and revenue of $19.10 million.
• The stock has recently traded up 7.3%, reaching $2.35, with analysts setting new price targets, most notably raising estimates to between $5.00 and $7.00.
• Institutional ownership stands at 67.77%, with Woodline Partners LP acquiring a new stake valued at approximately $1,054,000.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $19.10 million for the quarter.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $50.92 million for the quarter, compared to analysts' expectations of $35.42 million. CytomX Therapeutics had a net margin of 28.22% and a negative return on equity of 553.71%. During the same quarter last year, the company earned $0.17 earnings per share. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CytomX Therapeutics Trading Up 7.3%

NASDAQ:CTMX traded up $0.16 during mid-day trading on Friday, hitting $2.35. The stock had a trading volume of 1,446,668 shares, compared to its average volume of 3,167,910. The stock has a 50-day simple moving average of $2.41 and a two-hundred day simple moving average of $1.39. The company has a market capitalization of $189.46 million, a PE ratio of 4.90 and a beta of 2.05. CytomX Therapeutics has a twelve month low of $0.40 and a twelve month high of $3.10.

Analysts Set New Price Targets

CTMX has been the topic of a number of research analyst reports. HC Wainwright raised shares of CytomX Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price objective on the stock in a report on Thursday, May 15th. Piper Sandler raised their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Wall Street Zen raised shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th. Oppenheimer assumed coverage on CytomX Therapeutics in a research report on Thursday. They issued an "outperform" rating and a $7.00 target price for the company. Finally, Wedbush reissued an "outperform" rating and issued a $6.00 target price (up from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, CytomX Therapeutics currently has a consensus rating of "Buy" and an average price target of $5.75.

Hedge Funds Weigh In On CytomX Therapeutics

An institutional investor recently bought a new position in CytomX Therapeutics stock. Woodline Partners LP acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,657,306 shares of the biotechnology company's stock, valued at approximately $1,054,000. Woodline Partners LP owned 2.06% of CytomX Therapeutics as of its most recent filing with the Securities and Exchange Commission. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.